Author(s): Manisha Murali, Sudhakar Kothandan, Mithra Chandrasekaran, Sachin Kumar Singh, Gowthamarajan Kuppusamy, Arun Radhakrishnan

Email(s): arun.r@jssuni.edu.in

DOI: 10.5958/0974-360X.2021.00031.7   

Address: Manisha Murali1, Sudhakar Kothandan1, Mithra Chandrasekaran1, Sachin Kumar Singh2, Gowthamarajan Kuppusamy1, Arun Radhakrishnan1*
1Department of Pharmaceutics, JSS College of Pharmacy (JSS Academy of Higher Education & Research), Ooty.
2School of Pharmaceutical Sciences, Lovely Professional University, Punjab.
*Corresponding Author

Published In:   Volume - 14,      Issue - 1,     Year - 2021


ABSTRACT:
Personalized medicine or precision medicine is a preventive standard that splits people into distant groups with pharmaceutical accord, method, mediation and products are being made to measure to the entity case based on their forecast response or hazard of infection. The Promise of Personalized Medicine, “therapy with the right drug at the right dose in the right patient” is a description of how personalized medicine will affect the future of treatment. A form of a patient’s heredity abnormality can guide the choice of drugs or treatment custom to physicians that will diminish the harmful side effects or ensure the more successful outcomes. Personalized medicine reduces the cost of drugs, adverse drug reactions to patients and Increasing patient compliance with treatment. As Fluticasone and cyclophosphamide has high inter-individual variability, genetic polymorphism and population pharmacokinetics was studied, in-order to provide optimum dose for all individuals. Genetic Polymorphism associated with fluticasone was ABCB1 and CYP3A4*22, whereas genetic polymorphism associated with cyclophosphamide was CYP2B6 and GSTP1. Population Pharmacokinetics of fluticasone was done in different places using the co-factors such as genetic polymorphism, Alcohol consumption, weight, Height, Age and Smoking, whereas population pharmacokinetics of cyclophosphamide was done using co-factors such as Genetic polymorphism, Age, Body weight, Liver dysfunction. From the information obtained from population pharmacokinetics, a personalized chart for fluticasone and cyclophosphamide was constructed. In this study, genetic polymorphism and population pharmacokinetics of Fluticasone and Cyclophosphamide towards Personalized medicine was carried out.


Cite this article:
Manisha Murali, Sudhakar Kothandan, Mithra Chandrasekaran, Sachin Kumar Singh, Gowthamarajan Kuppusamy, Arun Radhakrishnan. Fluticasone and Cyclophosphamide towards the track of personalized Medicine. Research J. Pharm. and Tech. 2021; 14(1):179-184. doi: 10.5958/0974-360X.2021.00031.7

Cite(Electronic):
Manisha Murali, Sudhakar Kothandan, Mithra Chandrasekaran, Sachin Kumar Singh, Gowthamarajan Kuppusamy, Arun Radhakrishnan. Fluticasone and Cyclophosphamide towards the track of personalized Medicine. Research J. Pharm. and Tech. 2021; 14(1):179-184. doi: 10.5958/0974-360X.2021.00031.7   Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-1-31


REFERENCE:
1.    Vogenberg FR, Barash CI, Pursel M. Personalized medicine: part 1: evolution and development into theranostics. Pharmacy and Therapeutics. 2010 Oct;35(10):560.
2.    Cutter GR, Liu Y. Personalized medicine: The return of the house call?. Neurology: Clinical Practice. 2012 Dec 1;2(4):343-51.
3.    Mathur S, Sutton J. Personalized medicine could transform healthcare. Biomedical Reports. 2017 Jul 1;7(1):3-5.
4.    Risk for psychological distress among cancer patients with a familial history of Indian Residential School attendance: Results from the 2008‐10 First Nations Regional Health Survey: Mrs. Maike van Niekerk, Dr. Amy Bombay, Dalhousie University, Halifax, Canada; Dalhousie University, Halifax, Canada
5.    Individualized Drug Response Related To Genetic Variations Of Cytochrome P450 Isoforms And Other Enzymes Marian Sorin Paveliu, Simona Bengea, Fraga Silvia Paveliu 1 ”Titu Maiorescu” University, Faculty Of Medicine And Dental Medicine, Department Of Pharmacology, Bucharest, Romania 2” Dr. Paveliu” Medical Civil Society, Bucharest, Romania
6.    Brunicardi FC, Gibbs RA, Wheeler DA, Nemunaitis J, Fisher W, Goss J, Chen C. Overview of the development of personalized genomic medicine and surgery. World Journal of Surgery. 2011 Aug 1; 35(8):1693-9
7.    Maggi E, Patterson NE, Montagna C. Technological advances in precision medicine and drug development. Expert review of precision medicine and drug development. 2016 May 3; 1(3):331-43.
8.    Duignan PJ, Van Bressem MF, Baker JD, Barbieri M, Colegrove KM, De Guise S, De Swart RL, Di Guardo G, Dobson A, Duprex WP, Early G. Phocine distemper virus: Current knowledge and future directions. Viruses. 2014 Dec; 6(12): 5093-134
9.    Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis. Drugs. 2007 Apr 1; 67(6):887-901.
10.    1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015 Oct; 526(7571):68-74
11.    Aneesh TP, Sekhar S, Jose A, Chandran L, Zachariah SM. Pharmacogenomics: the right drug to the right person. Journal of Clinical Medicine Research. 2009 Oct; 1(4):191.
12.    Pavelić K, Martinović T, Pavelić SK. Do we understand the personalized medicine paradigm?. EMBO reports. 2015 Feb 1; 16(2):133-6..
13.    Esplin ED, Oei L, Snyder MP. Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease. Pharmacogenomics. 2014 Nov;15(14):1771-90.
14.    Knowles L, Luth W, Bubela T. Paving the road to personalized medicine: recommendations on regulatory, intellectual property and reimbursement challenges. Journal of Law and the Biosciences. 2017 Dec; 4(3): 453-506.
15.    Mangin D, Bahat G, Golomb BA, Mallery LH, Moorhouse P, Onder G, Petrovic M, Garfinkel D. International Group for Reducing Inappropriate Medication Use and Polypharmacy (IGRIMUP): position statement and 10 recommendations for action. Drugs and Aging. 2018 Jul 1;35(7):575-87
16.    Gottlieb A, Stein GY, Ruppin E, Sharan R. PREDICT: a method for inferring novel drug indications with application to personalized medicine. Molecular Systems Biology. 2011 Jan 1;7(1)
17.    Contributing Factors to the Adoption of Personalized Medicine https://www.zdnet.com/article/3-factors-needed-to-make-personalized-medicine-mainstream/
18.    Khoury MJ, Gwinn ML, Glasgow RE, Kramer BS. A population approach to precision medicine. American Journal of Preventive Medicine. 2012 Jun 1;42(6):639-45.
19.    Alahmari AD, Patel AR, Kowlessar BS, Mackay AJ, Singh R, Wedzicha JA, Donaldson GC. Daily activity during stability and exacerbation of chronic obstructive pulmonary disease. BMC Pulmonary Medicine. 2014 Dec;14(1):98
20.    Decramer ML, Hanania NA, Lötvall JO, Yawn BP. The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease. 2013; 8:53
21.    Gurney H, Wong M, Balleine RL, Rivory LP, McLachlan AJ, Hoskins JM, Wilcken N, Clarke CL, Mann GJ, Collins M, Delforce SE. Imatinib disposition and ABCB1 (MDR1, P‐Glycoprotein) genotype. Clinical Pharmacology and Therapeutics. 2007 Jul; 82(1):33-40.
22.    Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. The Lancet. 2009 Aug 29; 374(9691):733-43
23.    Mazzone E, Martinelli D, Berardinelli A, Messina S, D’Amico A, Vasco G, Main M, Doglio L, Politano L, Cavallaro F, Frosini S. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscular Disorders. 2010 Nov 1;20(11):712-6
24.    Gurney H, Wong M, Balleine RL, Rivory LP, McLachlan AJ, Hoskins JM, Wilcken N, Clarke CL, Mann GJ, Collins M, Delforce SE. Imatinib disposition and ABCB1 (MDR1, P‐Glycoprotein) genotype. Clinical Pharmacology and Therapeutics. 2007 Jul; 82(1):33-40.
25.    Kasper S, Sacher J, Klein N, Mossaheb N, Attarbaschi-Steiner T, Lanzenberger R, Spindelegger C, Asenbaum S, Holik A, Dudczak R. Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. International Clinical Psychopharmacology. 2009 May 1; 24(3):119-25.
26.    Kohansal R, Martinez-Camblor P, Agustí A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. American Journal of Respiratory and Critical Care Medicine. 2009 Jul 1; 180(1):3-10.
27.    Mazzone PJ. Preoperative evaluation of the lung cancer resection candidate. Expert review of respiratory medicine. 2010 Feb 1; 4(1):97-113.
28.    Mills EJ, Druyts E, Ghement I, Puhan MA. Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clinical Epidemiology. 2011; 3:107
29.    Singh D, Nicolini G, Bindi E, Corradi M, Guastalla D, Kampschulte J, Pierzchała W, Sayiner A, Szilasi M, Terzano C, Vestbo J. Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD. BMC Pulmonary Medicine. 2014 Dec 1; 14(1):43.
30.    Shah RR, Gaedigk A. Precision medicine: does ethnicity information complement genotype-based prescribing decisions?. Therapeutic Advances in Drug Safety. 2018 Jan; 9(1):45-62
31.    Chang TK, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Research. 1993 Dec 1; 53(23):5629-37
32.    Chang TK, Yu L, Maurel P, Waxman DJ. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Research. 1997 May 15; 57(10):1946-54.
33.    Roy P, Li JY, Crespi CL, Waxman DJ. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metabolism and Disposition. 1999 Jun 1; 27(6):655-66.
34.    Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochemical Pharmacology. 2000 Apr 15; 59(8):961-72
35.    Fleming RA. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 1997 Sep 10; 17(5P2):146S-54S
36.    Abdel-Rahman SZ, El-Zein RA, Anwar WA, Au WW. A multiplex PCR procedure for polymorphic analysis of GSTM1 and GSTT1 genes in population studies. Cancer letters. 1996 Oct 22; 107(2):229-33
37.    Arencibia DF, Rosario LA, Morffi J, Curveco D. Estrategias en las evaluaciones genotóxicas. Retel. 2009;23(3):23-40
38.    Au WW, Oh HY, Grady J, Salama SA, Heo MY. Usefulness of genetic susceptibility and biomarkers for evaluation of environmental health risk. Environmental and Molecular Mutagenesis. 2001; 37(3):215-25.
39.    Bolt HM, Thier R. Relevance of the deletion polymorphisms of the glutathione S-transferases GSTT1 and GSTM1 in pharmacology and toxicology. Current Drug Metabolism. 2006 Aug 1; 7(6):613-28.
40.    Porcellini A, Manna A, Moretti L, Carotenuto M, Greco MM, Bodenizza C. Busulfan and cyclophosphamide as conditioning regimen for autologous BMT in acute lymphoblastic leukemia. Bone Marrow Transplantation. 1989 May; 4(3):331-3
41.    Lucarelli G, Polchi P, Izzi T, Manna M, Delfini C, Galimberti M, Porcellini A, Moretti L, Manna A, Sparaventi G. Marrow Transplantation for Thalassemia after Treatment with Busulfan and Cyclophosphamide a. Annals of the New York Academy of Sciences. 1985 Jun; 445(1):428-31

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available